Baader Bank Aktiengesellschaft Sells 2,194 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Baader Bank Aktiengesellschaft cut its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 15.3% during the fourth quarter, HoldingsChannel.com reports. The firm owned 12,141 shares of the biotechnology company’s stock after selling 2,194 shares during the period. Baader Bank Aktiengesellschaft’s holdings in Exelixis were worth $404,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Los Angeles Capital Management LLC lifted its position in shares of Exelixis by 124.0% during the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after buying an additional 991,494 shares during the period. Caisse DE Depot ET Placement DU Quebec acquired a new position in Exelixis during the third quarter worth $14,979,000. Burney Co. acquired a new stake in shares of Exelixis in the 4th quarter valued at $12,267,000. Robeco Institutional Asset Management B.V. grew its holdings in shares of Exelixis by 263.1% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 483,064 shares of the biotechnology company’s stock worth $12,536,000 after purchasing an additional 350,026 shares during the last quarter. Finally, Retirement Systems of Alabama increased its position in shares of Exelixis by 24.6% during the 3rd quarter. Retirement Systems of Alabama now owns 911,497 shares of the biotechnology company’s stock worth $23,653,000 after purchasing an additional 180,021 shares in the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Exelixis Price Performance

Shares of EXEL stock opened at $32.93 on Friday. The stock has a market cap of $9.40 billion, a PE ratio of 21.11, a price-to-earnings-growth ratio of 0.72 and a beta of 0.53. The stock has a 50-day moving average of $34.73 and a 200-day moving average of $30.01. Exelixis, Inc. has a one year low of $20.01 and a one year high of $37.59.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The firm had revenue of $539.50 million during the quarter, compared to the consensus estimate of $490.31 million. During the same quarter in the prior year, the firm earned $0.10 earnings per share. The business’s quarterly revenue was up 14.3% on a year-over-year basis. As a group, research analysts anticipate that Exelixis, Inc. will post 1.74 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have commented on EXEL. TD Cowen boosted their price target on shares of Exelixis from $27.00 to $34.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Stifel Nicolaus raised their price target on Exelixis from $26.00 to $30.00 and gave the company a “hold” rating in a report on Wednesday, October 16th. JMP Securities reissued a “market outperform” rating and issued a $41.00 price objective on shares of Exelixis in a research note on Thursday, January 23rd. The Goldman Sachs Group upgraded Exelixis to a “strong sell” rating in a research note on Tuesday, October 15th. Finally, Oppenheimer downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $41.00 to $33.00 in a research report on Friday, January 24th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $36.06.

Insider Activity at Exelixis

In related news, EVP Jeffrey Hessekiel sold 60,000 shares of the firm’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the sale, the executive vice president now directly owns 486,059 shares in the company, valued at $17,823,783.53. This trade represents a 10.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Dana Aftab sold 96,986 shares of the stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $35.00, for a total value of $3,394,510.00. Following the transaction, the executive vice president now owns 498,945 shares of the company’s stock, valued at approximately $17,463,075. This trade represents a 16.27 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 208,574 shares of company stock worth $7,376,374 in the last quarter. Corporate insiders own 2.85% of the company’s stock.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.